A Nausea-Specific Quality-of-Life Benefit Did Not Establish Better Overall Health Utility
THC/CBD improved the nausea-related quality-of-life scale in the chemotherapy trial, but the broader health-utility comparison was nonsignificant. The two findings measured different aspects of patient experience.
The questionnaires were not interchangeable
The Functional Living Index–Emesis assessed the impact of nausea and vomiting. The trial also used the broader Assessment of Quality of Life–eight dimensions instrument, covering domains such as independent living, mental health and relationships. Baseline-adjusted models compared follow-up scores.
Benefit was concentrated in a specific measure
The nausea summary score favored THC/CBD, while evidence for the vomiting summary score was limited. The broader summary utility did not significantly differ between groups. A favorable pain-domain comparison did not establish improvement across the remaining domains.
Preserve both the benefit and the null
Reducing nausea-related disruption can matter clinically even without a demonstrated overall utility advantage. Conversely, a significant symptom-specific score cannot be renamed a general improvement in every aspect of life. These were secondary comparisons in a trial reporting multiple outcomes without multiplicity adjustment. They support a more precise account of the experience accompanying antiemetic treatment, not a claim of improved cancer prognosis, universal wellbeing or unaffected everyday function.
Related analysis: the trial’s main results and limitations.
